RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting.
Negatively charged magnetic liposomes were prepared using soya lecithin (Soya PC), cholesterol and phosphatidyl serine (PS) for their preferential presentation to circulating blood phagocytes (monocytes and neutrophils). PS ratio was optimized in terms of drug and magnetite loading, in vitro magnetic responsiveness and ex vivo monocytes/neutrophils uptake. RGD peptide was covalently coupled to the negatively charged liposomes composed of PC, cholesterol, PS and phopsphatidyl ethanolamine (PE) via carbodiimide-mediated coupling. In vivo cellular sorting study under magnetic guard indicated an increase in relative count of neutrophils and monocytes. Results suggest that selective uptake of RGD-anchored magnetic liposomes by these cells imparts them magnetic property. High levels of a model drug diclofenac sodium was quantified in target organ brain. In case of negatively charged uncoated magnetic liposomes brain levels of the drug was 5.95-fold compared to free drug and 7.58-fold in comparison to non-magnetic formulation, while for RGD-coated magnetic liposomes this ratio was 9.1-fold compared to free drug solution, 6.62-fold compared to non-magnetic RGD-coated liposomes and 1.5-fold when compared to uncoated magnetic liposomes. Liver uptake was significantly bypassed (37.2% and 48.3% for uncoated and RGD-coated magnetic liposomes, respectively). This study suggested the potential of negatively charged and RGD-coated magnetic liposomes for monocytes/neutrophils-mediated active delivery of drugs to relatively inaccessible inflammatory sites, i.e. brain. The study opens a new perspective of active delivery of drugs for a possible treatment of cerebrovascular diseases.
Jain
Sanyog
S
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, M.P. 470 003, Sagar, India.
Mishra
Vivek
V
Singh
Paramjit
P
Dubey
P K
PK
Saraf
D K
DK
Vyas
S P
SP
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism; D001812:Blood-Brain Barrier; D002851:Chromatography, High Pressure Liquid; D003911:Dextrans / Q000737:chemistry; D004008:Diclofenac / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism; D004660:Encephalitis / Q000378:metabolism; D005260:Female; D052203:Ferrosoferric Oxide; D007501:Iron / Q000737:chemistry; D008081:Liposomes / Q000737:chemistry; D008280:Magnetics; D008297:Male; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D009000:Monocytes / Q000166:cytology / Q000378:metabolism*; D009504:Neutrophils / Q000166:cytology / Q000378:metabolism*; D009842:Oligopeptides / Q000737:chemistry*; D009994:Osmolar Concentration; D010087:Oxides / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D013499:Surface Properties; D014018:Tissue Distribution
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003911:Dextrans; D008081:Liposomes; D009842:Oligopeptides; D010087:Oxides; D004008:Diclofenac; C047981:arginyl-glycyl-aspartic acid; D007501:Iron; D052203:Ferrosoferric Oxide